MORE►
influenza
TFF Pharmaceuticals CEO Dr. Harlan Weisman [Photo TFF, Background DI Studio]
Fort Worth’s TFF Pharmaceuticals Partners to Develop Dry Powder-Inhaled mRNA Treatment for Flu and COVID
by David Seeley | Sep 13, 2024
Respiratory illnesses like influenza and COVID can change rapidly, requiring the nimble development and delivery of antiviral drugs to combat them. TFF is now partnering with Atlanta's Emory University and the Biomedical Advanced Research and Development Authority (BARDA) to test the feasibility of converting an Emory-developed mRNA antiviral into a dry powder formulation that needs no cold-chain storage.
